Higher percentage of CD133+ cells is associated with poor prognosis in colon carcinoma patients with stage IIIB
Chun-Yan Li1,2,5, Bao-Xiu Li1,2,6, Yi Liang1,4, Rui-Qing Peng1,2, Ya Ding1,2, Da-Zhi Xu1,3, Xin Zhang1,2, Zhi-Zhong Pan1,3, De-Sen Wan1,3, Yi-Xin Zeng1,2,4, Xiao-Feng Zhu1,4 and Xiao-Shi Zhang*1,2

Address: 1State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-sen University, Guangzhou, PR China, 2Biotherapy Center, Cancer Center, Sun Yat-sen University, Guangzhou, PR China, 3Department of Abdominal Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, PR China, 4Department of Experimental Research, Cancer Center, Sun Yat-sen University, Guangzhou, PR China, 5Biotherapy Center, The First Affiliated Hospital, Chongqing Medical University, Chongqing, China and 6GuangZhou First Municipal People's Hospital, Guangzhou, China

Email: Chun-Yan Li - lichyanun@hotmail.com; Bao-Xiu Li - libaoxiu@csco.org.cn; Yi Liang - liangyi_best@163.com; Rui-Qing Peng - gz13724083175@126.com; Ya Ding - dingya@mail.sysu.edu.cn; Da-Zhi Xu - dazhi@163.com; Xin Zhang - xingzhang@hotmail.com; Zhi-Zhong Pan - panzhzh@mail.sysu.edu.cn; De-Sen Wan - wds-fk@yahoo.com.cn; Yi-Xin Zeng - zengyix@mail.sysu.edu.cn; Xiao-Feng Zhu - zuxfeng@mail.sysu.edu.cn; Xiao-Shi Zhang* - zxs617@hotmail.com

* Corresponding author

Abstract

Background: Cancer stem cell model suggested that tumor progression is driven by the overpopulation of cancer stem cells and eradicating or inhibiting the symmetric division of cancer stem cells would become the most important therapeutic strategy. However, clinical evidence for this hypothesis is still scarce. To evaluate the overpopulation hypothesis of cancer stem cells the association of percentage of CD133+ tumor cells with clinicopathological parameters in colon cancer was investigated since CD133 is a putative cancer stem cell marker shared by multiple solid tumors.

Patients and methods: Tumor tissues matched with adjacent normal tissues were collected from 104 stage IIIB colon cancer patients who were subject to radical resection between January, 1999 to July, 2003 in this center. The CD133 expression was examined with immunohistochemical staining. The correlation of the percentage of CD133+ cell with clinicopathological parameters and patients’ 5-year survival was analyzed.

Results: The CD133+ cells were infrequent and heterogeneous distribution in the cancer tissue. Staining of CD133 was localized not only on the glandular-luminal surface of cancer cells but also on the invasive budding and the poorly differentiated tumors with ductal structures. Both univariate and multivariate survival analysis revealed that the percentage of CD133+ cancer cells and the invasive depth of tumor were independently prognostic. The patients with a lower percentage of CD133+ cancer cells (less than 5%) were strongly associated with a higher 5-year survival rate than those with a higher percentage of CD133+ cancer cells (greater than or equal to 55%). Additionally, no correlation was obtained between the percentage of CD133+ cancer cells and the other clinicopathological parameters including gender, age, site of primary mass, pathologic types, grades, and invasive depth.

Conclusion: The fact that a higher percentage CD133+ cells were strongly associated with a poorer prognosis in patients with locally advanced colon cancer implicated that CD133+ cancer cells contribute to the tumor progression, and the overpopulation hypothesis of cancer stem cell seems reasonable.
Background

Colorectal cancer is one of the most common causes of cancer death worldwide. Although the median overall survival of patients with metastatic colorectal cancer has increased from 12 months to approximately 24 months over the past decade as a result of an improvement in systemic therapies including new chemotherapeutic agents such as CPT-11 and oxaliplatin and monoclonal antibodies against EGFR (cetuximab and panitumumab) and VEGF (bevacizumab), the 5-year survival is still pessimistic [1-4]. Therefore, one of the main challenges in colorectal carcinoma remains to develop new strategies beyond chemotherapy to inhibit the disease progression.

A growing body of evidence supports the notion that only a small subset of cells within a solid tumor have 'stem-like' characteristics. These tumor-initiating cells, or cancer stem cells, distinct from non-malignant stem cells, show low proliferative rates, high self-renewal capacity, propensity to differentiate into active proliferating tumor cells, and resistance to chemotherapy or radiation [5,6]. Until now, cancer stem cells have been identified in a great deal of solid tumors [5-8].

Multiple cancer stem cell-associated markers have been identified, among which CD133 has received considerable attention. CD133 or prominin-1 gene is located on chromosome 4p15.32 and encodes a cell surface glycoprotein compromising five transmembrane domain and two large glycosylated extracellular loops [9,10]. The transcription of CD133 can be initiated at five tissue specific promoters, yielding eight alternatively spliced transcripts [11-13]. Epigenetic mechanism is involved in the regulation of CD133 expression [14-16]. Although the function of CD133 is unknown, preliminary evidence proposed that expression of CD133 is associated with the activation of stemness-related signal pathway, resistance to apoptosis and bioenergetic stress [17-22]. Initially identified in hematopoietic stem cells, CD133 is now shared as cancer stem cell marker across multiple kinds of solid tumors, such as those in the brain, breast, lung, liver, colon, prostate, pancreatic carcinomas, medulloblastoma, and melanoma [5-7,23-29].

As for colorectal cancer, initially, Ricci-vitiani and O’Brien observed that colon cancer stem cells are located in the CD133+ subpopulation, which accounts for approximately 2.5% of the tumor cells [30,31]. Subsequently, Dalerba and Haraguchi reported that markers for colon cancer stem cells are EpCAM hi/CD44+/CD166+ [32,33]. In addition, Barker proposed that Lgr5 is another marker [34]. CD133+ colon cancer cells include EpCAM hi/CD44+ cells, whereas the relationship between CD133+ subset and Lgr5+ subset is unclear. Therefore, which protein would be an ideal marker for colorectal cancer stem cells remains an open question.

Based on the mathematic model, the hypothesis that development of colorectal carcinoma is driven by overpopulation of stem cells has been suggested. It is believed that the abundance of cancer stem cells is derived from their symmetric division, whereas their normal partners are subject to asymmetric division, therefore, eradicating or inhibiting the symmetric division of cancer stem cells would become the most important strategy for cancer treatment [35-39]. If the percentage of cancer stem cells is associated with the prognosis of cancer patients, the overpopulation hypothesis would be substantially supported. By now, the relationship between the percentage of CD133 and prognosis of colorectal carcinomas was controversial. Horst reported that CD133 expression is an independently prognostic marker whereas this kind of correlation was not confirmed by Kojima[40,41]. Accordingly, more evidence was need to elucidate the relationship between the percentage of CD133+ tumor cells and the prognosis of colorectal cancer patients. This study showed that the percentage of CD133+ tumor cells was associated with the prognosis among patients with locally advanced colon cancers, implicating that CD133+ cells are involved in the progression of colon cancer.

Patients and methods

Patients and Follow-up

104 cases of pathologically confirmed specimens were obtained from colon carcinoma patients with TNM stage IIIB (the depth of primary invasive spread defined as T3 and T4 with one to three regional node involvement but no distant metastasis) who were subject to radical resection between January, 1999 and July, 2003 in the Cancer Center of Sun Yat-Sen University, Guangzhou, China. None of the patients had undergone either chemotherapy or radiotherapy before the collection of the samples. All of them were subject to 5-Fu based postoperatively adjuvant chemotherapy for six months. Patients were observed on an every-three-month basis during the first year, once every 6 months in the second year, and by telephone or mail communication once every year thereafter for a total of 5 years. If recurrence or metastasis occurred, 5-Fu based chemotherapy was given according to the NCCN guideline. Overall survival was defined as the time from operation to death or was censored at the last known alive data. Histopathologic characteristics were confirmed by blinded review of the original pathology slides. The TNM classification was used for pathologic staging, and the World Health Organization classification was used for pathologic grading.

Immunohistochemical assay

The expression of CD133 in primary tumors matched with adjacent noncancerous tissue was examined with immunohistochemical assay. Briefly, formalin-fixed, paraffin-embedded archived tissues were subject to 4-μm section. Then, sections were subject to dewax, rehydration,
blocking with hydrogen peroxide, and antigen retrieval with microwave in a 10 mM citrate buffer (pH 6.0) for 10 min and cooled to room temperature. After being blocked with 1% goat serum albumin sections were incubated with the mouse monoclonal antibodies against human CD133 at a dilution of 1:150 (Abcam, Cambridge, UK) overnight at 4°C, followed with horseradish peroxidase-labeled secondary antibodies for 30 minutes at room temperature. The sections were developed with diaminobenzidine tetrahydrochloride (DAB) and counterstained with hematoxylin. Immunohistochemical assay was performed within 7 days of section preparation. To prevent antigen degradation sections were stored at 4°C before immunohistochemical analysis. Tissue derived from glioma was used as positive control and negative controls were made with primary antibody replaced by PBS.

Referring to Maeda’s method, slides were examined under low power (×40 ~ ×200) microscope to identify the regions containing the highest percentage of CD133+ cells (hot spot) in the cancer nest [42]. Ten fields of hot spot inside the tumor tissue were selected, and expression of CD133 was evaluated in 1000 tumor cells (100 cells per field) with high power (×400) microscopy. Specimens were defined as positive for CD133 expression if there were tumor cells distinctly stained by the anti-CD133 antibodies. The percentage of CD133 + cells was classified into two levels: < 5% CD133-positive cells and ≥5% CD133-positive cells [42].

Statistical analysis
The following factors were assessed with both univariate and multivariate analyses for their influence on overall survival: gender, age (<60 years old vs ≥ 60 years old), sites of primary mass (left hemicolon vs right hemicolon), the T stages (the depth of primary invasive spread, T3 vs T4), pathological classifications (papillary carcinoma and tubular adenocarcinoma vs mucoid adenocarcinoma and signet ring cell carcinoma), tumor grades (the degree of cellular differentiation, well differentiated, G1 vs moderate differentiated, G2 vs poorly differentiated, G3), and the percentage of the CD133+ cells (≤5% positive vs ≥5% positive). The nonparametric correlation Kendall’s tau-b test was used to assess associations between categorical variables. Kaplan-Meier curves were used to estimate the distributions of clinicopathological characteristics to survival and compared with the log-rank test. The Cox regression model was used to correlate assigned variables with overall survival. All statistical analyses were carried out using SPSS 15.0 software (SPSS Inc, Chicago, IL, USA). Statistical significance was assumed for a two-tailed P < 0.05.

Results

Expression of CD133 in tumor tissue
CD133 brownish signals were observed on the cell membrane, especially on its luminal and basal surface. In general, the cases with intensive staining of CD133 had higher percentage of CD133+ tumor cells. Several nests with intensive CD133 staining, so-called “hotspot” could always be seen within the field of cancer nests microscopically (Fig 1A to 1D). The cancer cells within an adenocarcinoma nest could actively proliferate and form a group of cells, which invaded into the surrounding tissue, so-called “budding”, and showed negative or weak staining against CD133 (Fig 1E). Besides staining on the well differentiated tumors CD133 staining was documented on the poorly differentiated tumors with ductal structures rather than those without ductal structures (Fig 1F). The paratuborous normal intestinal epithelium could be found in 72 out of 104 specimens used for this study. The CD133 expression of normal intestinal epithelium was only found in 7 out of the 72 specimens.

Referring to Maeda’s method the percentage of CD133+ cells was classified into two levels: < 5% CD133+ cells and ≥ 5% CD133+ cells [39]. In this group of patients, 62 cases...
of 104 (59.6%) specimens contained less than 5% CD133-positive tumor cells and 42 cases (40.4%) contained more than 5% CD133-positive tumor cells, among which the percentage of CD133+ cells varying from 5% to 25% existed in 23 cases, from 26% to 50% in 12 cases, and more than 50% in 7 cases.

**Relationship between the percentage of CD133+ cells and clinicopathological characteristics**

No correlation was observed between the expression of CD133 and clinicopathological parameters such as age, gender, sites of primary mass, pathological classifications, invasive depth, and tumor grades. Otherwise, the analysis revealed that mucoid adenocarcinomas and signet ring cell carcinomas had the potential with poorer differentiation (r = 0.459, P < 0.001) and higher frequency occurred in the right hemicolon (r = 0.215, P = 0.022) (Tab 1).

**Relationship between survival and clinicopathological characteristics assessed with univariate survival analysis**

By the end of the 5-year follow-up, 67 cases were still alive. So, the 5-year survival rate was 64.4%. Kaplan-Meier analysis revealed that the percentage of CD133+ cells in cancer nests and the invasive depth of primary mass were prognostic. The 5-year survival rate among patients with a higher percentage of CD133+ cells (≥5%) in the cancer nests was 45.2%, whereas those with a lower percentage of CD133+ cells (<5%) was 77.4% (P = 0.001). In addition, the 5-year survival rate among patients with T3 tumors (tumors which invade through the muscular propria into the subserosa, or into nonperitonealized pericolic tissue) was 69.6%, whereas the 5-year survival rate among patients with T4 tumors (tumors which perforate the visceral peritoneum or directly invade other organs or structure) was 25.0% (P = 0.001) (Tab 2).

**Relationship between survival and clinicopathological characteristics assessed with multivariate survival analysis**

The Cox regression model revealed that the patients with a lower percentage CD133+ cells (<5%) in the cancer nests were significantly associated with a higher 5-year survival rate with -0.987 in partial regression coefficient and 0.373 (95% CI 0.190 ~ 0.732) in relative risk (P = 0.004). Additionally, a higher T stage (invasive depth) was significantly associated with a lower survival rate with 1.209 in partial regression coefficient and 3.351 (95% CI 1.558 ~ 7.208) in relative risk (P = 0.002). Therefore, the percentage of CD133+ cells in cancer nests and T stage were independently prognostic factors. No relationship was observed between the survival and the other clinicopathological parameters such as age, gender, site of primary mass, pathological classifications, and grades (Tab 2, Fig 2).

**Discussion**

This study showed that a higher percentage of CD133+ cells in cancer nests was strongly associated with the lower 5-year survival rate in colon cancer patients with stage IIIB, a locally advanced disease among which most of patients would die from metastasis in spite of adjuvant chemotherapy, implying that the overpopulation hypothesis of cancer stem cell seems reasonable as CD133 is a putative marker of colon cancer stem cells.

The evidence concerning the correlation of the percentage of CD133+ tumor cells with the prognosis of patients was scarce as a few of observations were reported [43-46]. Recently the relationship between CD133 expression and prognosis in colorectal carcinomas was examined. Horst reported that CD133 expression is an independently prognostic marker whereas this kind of correlation was not observed by Kojima. [40,41] The discrepancy might derive from inadequate patient quantity and the mixed tumor stage. For example, in Kojima’s study, a total of 189 patients consisted of 106 cases of colon cancers and 83 cases of rectal cancers with TNM stages varying from I to VI, that is, one group of patients with a definite stage contained only 20 or 30 cases of colon or rectal cancer patients, respectively[41]. Similar situation existed in Horst’s study [40]. To narrow the heterogeneity of patients.

### Table 1: Correlations of CD133 expression with clinicopathological parameters in the Stage IIIB colon carcinomas

| Variables                  | gender | age  | Invasive depth | Sites of primary mass | Grades    | Pathological classifications | The percentage of CD133+ cells |
|----------------------------|--------|------|---------------|-----------------------|-----------|-------------------------------|-------------------------------|
| gender                     | P      | .    | .242          | .541                  | .792      | .129                          | .129                          | .785                           |
| age                        | P      |      | .242          | .541                  | .792      | .129                          | .129                          | .785                           |
| Invasive depth             | P      |      | .242          | .541                  | .792      | .129                          | .129                          | .785                           |
| Sites of primary mass      | P      |      | .242          | .541                  | .792      | .129                          | .129                          | .785                           |
| Grades                     | P      |      | .242          | .541                  | .792      | .129                          | .129                          | .785                           |
| Pathological classifications| P      |      | .242          | .541                  | .792      | .129                          | .129                          | .785                           |
| The percentage of CD133+ cells | P    | .785 | .249          | .499                  | .895      | .936                          | .936                          | .895                           |

*: P < 0.05; **: P < 0.001
and make the results more reproducible, this study included 104 cases of colon carcinoma patients with stage IIIB. The results showed that CD133+ cancer cells contributed to the progression of colon cancer, arguing the Horst's observation.

The discrepancy concerning the pattern and the frequency of CD133 expression in colon cancer also existed between the studies mentioned above and this study. Horst and Kojima reported that CD133 antigen, stained with antibodies from Miltenyi Biotech, Sata Cruz Biotechnology, or Cell signaling, was localized exclusively on the glandular-luminal surface of colorectal cancer. Staining of the CD133 was observed neither on the budding cancer nest nor on poorly differentiated cancer cells [40,41]. However, in this study, being stained with antibodies from Abcam CD133 expression existed not only on the apical membrane but also on basal surface of tumor cells, both on the budding cancer nest (the invasive front) and on the poorly differentiated cancer cells, although the intensity of staining was weaker. This pattern of CD133 expression might be more likely consistent with the hypothesis that CD133+ cancer cells would reveal a more aggressive phenotype. Since the intensity of CD133 is cell cycle-depend-
Recently the representative of CD133 as marker of colon cancer stem cells was questioned. On the one hand, CD133+ colon cancer cells revealed 'stem-like' characteristics, and stem cells marked by CD133 was susceptible to transformation into tumors[49]. On the other hand, CD133 expression was detected not only on cancer cells, but also on the luminal layer of epithelium of digestion duct, on the mature epithelium of the pancreatic duct, on the proximal tubules of the kidney, and on the lactiferous ducts of the mammary gland [50-52]. Furthermore, both CD133+ and CD133- metastatic colon cancer cells initiated tumors[50]. Additionally, CD44+ cancer cells rather than CD133+ cells have an increased tumorigenicity[53]. Those data pointed that CD133 should not be a unique marker for colon cancer stem cells. It is less likely that a known marker for colon cancer stem cells, such as CD44, CD166, EpCAM, and Lgr5, has the potential just like Pten-related pathway in leukemia, which could distinguish hematopoietic stem cells from leukemia-initiating cells [54-57]. Collectively, a combination of cell surface markers is need for the definition of colon cancer stem cells [58-60]. This study implied that, given that CD133 may not represent all the entire cancer stem cells, it is still a useful biomarker as CD133+ cells is more aggressive than CD133- partners in colon cancer.

Figure 2
The association of overall survival with the percentage of CD133+ cells in colon carcinoma patients with Stage IIIB. The patients with a lower percentage of CD133+ cells (<5%) in the cancer nests were strongly associated with longer 5-year survival than those with a higher percentage of CD133+ cells (≥5%).

Conclusion
The fact that a higher percentage of CD133+ cells is strongly associated with a poorer prognosis implicates that CD133+ cells contribute to the progression of colon cancer, and the overpopulation hypothesis of cancer stem cell seems reasonable.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
XDZ, PRQ, DY, ZX, PZZ, and WDS carried out the cases collection, LCY and LY carried out the immunohistochemical staining work, LBX and ZXF analyzed results. ZXS and ZYX conceived of the study, participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgements
This study was supported by the National Nature Science Foundation (30872931) and the Nature Science Foundation of Guangdong Province, China (05001693). The authors thanked Prof. Yong-Shen Zong for his comment on the immunohistochemical analysis.

References
1. Meyerhardt JA, Mayer RJ: Systemic therapy for colorectal cancer. N Engl J Med 2005, 352(5):476-487.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2):71-96.
3. Omura K: Advances in chemotherapy against advanced or metastatic colorectal cancer. Digestion 2008, 77(Suppl 1):13-22.
4. Hecht JR: Current and emerging therapies for metastatic colorectal cancer: applying research findings to clinical practice. Am J Health Syst Pharm 2008, 65(11 Suppl 4):S15-21.
5. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100(7):3983-3988.
6. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB: Identification of human brain tumour initiating cells. Nature 2004, 432(7015):396-401.
7. Boman BM, Wicha MS: Cancer stem cells: a step toward the cure. J Clin Oncol 2008, 26(17):2795-2799.
8. Wang J, Guo LP, Chen LZ, Zeng YX, Lu SH: Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res 2007, 67(8):3716-3724.
9. Shmelkov SV, St Clair R, Lyden D, Rafi S: AC133/CD133/Promin-1. Int J Biochem Cell Biol 2005, 37(4):715-719.
10. Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Walker EB, Buck DW: A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997, 90(12):5013-5021.
11. Yu Y, Flint A, Dvorin EL, Bischoff J: AC133-2, a novel isoform of human AC133 stem cell antigen. J Biol Chem 2002, 277(23):20711-20716.
12. Bauer N, Fonseca AV, Florek M, Freund D, Jászai J, Bornhäuser M, Fargeas CA, Corbeil D: New insights into the cell biology of hematopoietic progenitors by studying prominin-1 (CD133). Cells Tissues Organs 2008, 188(1-2):127-138.
13. Jászai J, Fargeas CA, Florek M, Hutner WB, Corbeil D: Focus on molecules: prominin-1 (CD133). Exp Eye Res 2007, 85(5):585-586.
14. Baba T, Convery PA, Matsumura N, Whitaker RS, Kon doch E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, Marks JR, Berchuck A, Murphy SK: Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009, 28(2):209-218.
15. Tabu K, Sasaj K, Kimura T, Wang L, Aoyanagi E, Kohsaka S, Tanino M, Nishihara H, Tanaka S: Promoter hypomethylation regulates
CD133 expression in human gliomas. Cell Res 2008, 18(10):1037-1046.

16. Rieger D, Enas-Waser R, Dinger TC, Vallabhapurapu DS, Rolletschek A, Hacker C, Hieger E, Wobus AM, Muller AM, Zenke M: Pluripotency associated genes are reactivated by chromatin-modifying agents in neurosphere cells. Stem Cells 2008, 26(4):920-926.

17. Handbuszczynski D, Becker OJ, Holland EC: Cancer stem cells and survival pathways. J Cell Physiol 2008, 7(10):1371-1378.

18. Murat A, Migliavacca E, Janzer RC, Hegi ME: Stem Cell-Related "Self-Renewal" Signature and High Epidermal Growth Factor Receptor Expression Associated With Resistance to Concomitant Chemoradiotherapy in Glioblastoma. J Clin Oncol 2008, 26(18):3015-3024.

19. Hambardzumyan D, Squatrito M, Holland EC: Radiation resistance and stem-like cells in brain tumors. Cancer Cell 2006, 10(6):454-456.

20. Serio V, Chepe P, de Tribolet N, Radovanovic I, Ruiz I, Altaba A: HEDGEHOGLI signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 2007, 17(2):165-172.

21. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN: Glioma stem cells promote radiation resistance by preferential activation of the DNA damage response. Nature 2006, 444(7120):756-760.

22. Griguier CE, Oliva CR, Gobin E, Marcorelles P, Benos DJ, Lancaster JR Jr, Gillespie GT: CD133 is a marker of bioenergetic stress in human gliomas. PLoS ONE 2008, 3(11):e3655.

23. Yin AH, Miraglia S, Zanfini ED, Almeida-Porada G, Ogawa M, Leary AG, Oweus J, Kearney J, Buck DW: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997, 90(12):5002-5017.

24. Wright MH, Cagno AM, Salcido CD, Carlson MD, Ambudkar SV, Bankati A, Epperson FL, Sandri G, La Porta CA: Radiation resistance and stem-like properties of human colorectal cancer cells. Cancer Res 2008, 68(19):7540-7544.

25. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello sandri G, La Porta CA: Radiation resistance in human gliomas is associated with CD133 expression. Cancer Res 2008, 68(9):3304-3313.

26. Morrison SJ, Kajjo M: Asymmetric and symmetric stem-cell divisions in development and cancer. Nature 2006, 441(7097):1068-1074.

27. Johnston MD, Edwards CM, Bodmer WF, Maini PK, Chapman SJ: Mathematical modeling of cell population dynamics in the colon crypt and in colorectal cancer. Proc Natl Acad Sci USA 2008, 105(10):4008-4013.

28. Horst D, Kriegl L, Engel J, Kirchner T, Jung A: CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 2008, 99(8):1285-1289.

29. Kojima M, Ishii G, Atsumi N, Fujii S, Saito N, Ochiai A: Immunohistochemical detection of CD133 in colorectal cancer: a clinicopathological study. Cancer Sci 2008, 99(8):1578-1583.

30. Maeda S, Shinchi H, Kurahara H, Matsu Y, Maemura K, Sato M, Natsugoe S, Aikou T, Takao S: CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer 2008, 98(8):1389-1397.

31. Zeppinck F, Ahrami R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, Radwimmer B, Herold-Mende CC: Stem cell marker CD133 identifies clinical outcome in glioma patients. Clin Cancer Res 2008, 14(1):123-129.

32. Beier D, Wischuschen J, Dietmaier W, Hau P, Proescholdt M, Bravaliaki A, Bogdahn U, Beier CP: CD133 expression and cancer stem cells predict prognosis in high-grade oligodendrogliomas. Brain Pathol 2008, 18(3):370-377.

33. Song W, Li H, Tao K, Li R, Song Z, Zhao Q, Zhang F, Dou K: Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 2008, 62(8):1212-1218.

34. Zhang HZ, Wei YP, Wang M, Wu C, Yang YQ, Chen J, Cao YK: Association of CD133 and endothelin-converting enzyme expressions with prognosis of non-small cell lung carcinoma. Nan Fang Yi Ke Da Xue Xue Bao 2007, 27(5):696-9. [Article in Chinese]

35. Jakusch M, Muenzer J, Bajpai R, Terskikh A, Oshima RG: Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines. Cancer Res 2008, 68(19):7882-7886.

36. Rubio CA: Arrest of cell proliferation in budding tumor cells ahead of the invading edge of colorectal carcinomas. A preliminary report. Anticancer Res 2008, 28(4C):2417-2420.

37. Zhu L, Gibson P, Currie DS, Tong Y, Richardson JR, Bayazitov IT, Poppletten H, Zakharenko S, Ellison DW, Gilbertson RJ: Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 2009, 457(7229):603-607.

38. Smelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair R, Baljevic M, Jin DK, Chadburn A, Murphy AJ, Valenzuela DM, Gale NW, Thurston G, Yancopoulos GD, Angelika M, Kemeny N, Lyden D, Rafii S: CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 2008, 118(6):2111-2120.

39. Lardon J, Corbeil D, Huttner WB, Ling Z, Bouwens L: Stem cell marker prominin-1/AC133 is expressed in duct cells of the adult human pancreas. Pancreas 2008, 36(1):e1-6.

40. Florek M, Haase M, Marzescos AM, Freund D, Ehninger G, Huttner WB, Corbeil D: Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain hematopoietic outcomes. Cytometry A 2007, 70(1):15-26.

41. Chu P, Clanton DJ, Snipas TS, Lee J, Mitchell E, Nguyen ML, Hare E, Peach RJ: Characterization of a subpopulation of colon cancer cells with stem-like cell properties. Int J Cancer 2009, 124(6):1312-1321.

42. Lobo NA, Shimoso Y, Qian D, Clarke MF: The biology of cancer stem cells. Annu Rev Cell Dev Biol 2007, 23:675-699.

43. Merlo LM, Pepper JW, Reid BJ, Maley CC: Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006, 6(12):924-935.
56. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H, Morrison SJ: 
Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. 
Nature 2006, 441(7092):475-482.

57. Yilmaz OH, Morrison SJ: The PI-3 kinase pathway in hematopoietic stem cells and 
leukemia-initiating cells: a mechanistic difference between normal and cancer stem cells. 
Blood Cells Mol Dis 2008, 41(1):73-76.

58. Willis ND, Pryborski SA, Hutchison CJ, Wilson RG: Colonic and colorectal cancer 
stem cells: progress in the search for putative biomarkers. J Anat 2008, 213(1):59-65.

59. Shibata D: Stem cells as common ancestors in a colorectal cancer ancestral tree. 
Curr Opin Gastroenterol 2008, 24(1):59-63.

60. Zou GM: Cancer initiating cells or cancer stem cells in the gastrointestinal tract and liver. 
J Cell Physiol 2008, 217(3):598-604.